Kamada Ltd Dossier
Qualitative Analysis
Business overview
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) is a global biopharmaceutical company specializing in the development, production, and commercialization of specialty plasma-derived protein therapeutics. The company operates through two primary segments: the Proprietary Products segment, which generates the majority of its revenues, and the Distribution segment. Its commercial portfolio is highly diversified, anchored by key FDA-approved products including KEDRAB, GLASSIA, and CYTOGAM, alongside other specialty immunoglobulins such as WINRHO SDF, HEPAGAM B, and VARIZIG. Kamada markets its products in over 30 countries, leveraging both direct sales and strategic distribution partnerships, including a notable royalty-bearing relationship with Takeda for GLASSIA.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Ramping up plasma collection operations across three Texas-based centers (Beaumont, Houston, and San Antonio) to support vertical integration, reduce specialty plasma costs, and generate revenue through normal source plasma sales.
Expected impact: At full capacity, each of the Houston and San Antonio centers is expected to generate annual revenues of $8 million to $10 million from sales of normal source plasma.
Expanding the distribution segment in Israel by in-licensing and launching biosimilar products, primarily through a strategic partnership with Alvotech.
Expected impact: Targeting annual biosimilar sales of $15 million to $20 million within 4 to 5 years.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a portfolio of four FDA-approved plasma-derived hyperimmune commercial products (CYTOGAM, HEPAGAM B, VARIZIG, and WINRHO SDF) to establish Kamada as a global leader in specialty plasma therapies.
Financial impact: Significantly expanded the company's proprietary segment revenues and global commercial footprint.
Strategic Partnerships
Exclusive agreement to commercialize Alvotech's portfolio of biosimilar product candidates in Israel, positioning Kamada as a leader in the Israeli biosimilar market.
Terms: Kamada commercializes the products in Israel, while Alvotech maintains development, manufacturing, and supply responsibilities.
Strategic agreement for the clinical development and marketing of KEDRAB (Rabies IgG) in the U.S.
Terms: Kedrion has a minimum purchase commitment of $90 million in sales for 2026 through 2027.